Regulating of Reimbursement Prices of Drugs in the Slovak Republic

Systems of reimbursements within the European Union have relatively similar principle in most cases of the inclusion or case of non-inclusion the medicine into the positive list on the basis of the decision of the regulator or its authorized institution. Effectiveness in sharing of the costs increases by reducing of the excessive demand and the total drug expenses are regulated. Therefore, the existence of mechanisms for the protection before the high costs is a very important. One of the problems of Slovak public health were high public expenses on drugs and their considerable consumption and since joining into the OECD in 2000 Slovakia has regularly occupied the front position together with Hungary.